SAN CLEMENTE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended December 31, 2025. Fourth Quarter 2025 Results Fourth quarter 2025 revenue was $540.7 million, as compared to $629.8 million in the same period in the prior year. GAAP gross profit for the fourth quarter of 2025 was $203.0 million, as compared to $227.3 million in the same pe ...

Core Viewpoint - ICU Medical, Inc. is set to release its fourth quarter 2025 earnings results on February 19, 2026, followed by a conference call to discuss these results [1][2]. Group 1: Earnings Release Details - The earnings release will occur on Thursday, February 19, 2026, at approximately 4:00 p.m. ET (1:00 p.m. PT) [2]. - A conference call regarding the earnings results will take place at 4:30 p.m. ET (1:30 p.m. PT) on the same day [2]. - The conference call can be accessed via phone at (800) 274-8461 with the conference ID "ICUMED" and will also be available through a webcast on the company's website [2]. Group 2: Company Overview - ICU Medical is a global leader in infusion systems, infusion consumables, and high-value critical care products used in various healthcare settings [3]. - The company is headquartered in San Clemente, California, and focuses on providing quality, innovation, and value to clinical customers worldwide [3].

Core Viewpoint - ICU Medical is presenting its investment rationale and commitment to the company, highlighting a positive outlook following recent challenges and macroeconomic factors [2][3]. Group 1: Company Overview - ICU Medical's leadership team, including CEO Vivek Jain and CFO Brian Bonnell, is committed to addressing investor interests and simplifying communication [2][3]. - The company has experienced situational challenges in past transactions but is now positioned to move forward with a clearer strategy [3]. Group 2: Market Context - The presentation indicates that many macroeconomic challenges previously faced by the company are now behind them, suggesting a more stable environment for future growth [3].

ICU Medical FY Conference Summary Company Overview - **Company**: ICU Medical (NasdaqGS:ICUI) - **Industry**: IV Therapy - **Segments**: Consumables, Systems, Vital Care - **Revenue Sources**: Two-thirds of revenues and profits come from North America, with 87% of items being single-use disposables priced at $10 or less [3][4] Financial Metrics - **Equity Value**: Approximately $3.8 billion - **Net Debt**: About $1 billion, resulting in a leverage ratio of over 2.5 times [4] - **Revenue Growth**: Historical average growth of 5-7% in major business segments [9] - **Gross Margins**: Targeting 40% gross margins, currently at 41%, with potential for further improvement [22] Market Dynamics - **IV Therapy Industry**: Characterized by high demand, with 90% of hospital patients receiving infusion therapy. The industry has long product life cycles and high regulatory barriers, leading to a consolidated market with limited players [5][6] - **Growth Opportunities**: Identifying niches within the market that grow faster than the overall census, focusing on safety, clinical efficiency, and workflow improvements [6][19] Innovation and Product Development - **Investment in Innovation**: Over $100 million spent on developing new infusion pump systems and software, aiming for integrated solutions that enhance safety and efficiency [17][19] - **Product Launches**: Upcoming launches include Plum Dual, Plum Solo, and Medfusion 5000 syringe pump, which are expected to drive growth [24] - **Consumables Innovation**: Focused on improving patient safety and clinical workflows, leading to a billion-dollar business in consumables [20][21] Strategic Goals - **Revenue Growth**: Aiming for mid-single-digit growth through competitive share gains and focusing on faster-growing markets [11][12] - **Financial Health**: Plans to improve free cash flow and reduce net debt, with a clear capital allocation strategy to return capital to shareholders [23][24] - **Operational Challenges**: Addressing remaining integration issues from the Smiths Medical acquisition and managing tariff impacts [27][28] Conclusion - **Investment Rationale**: ICU Medical is positioned at an inflection point with new product cycles, consistent innovation, and improving financials. The company is focused on leveraging its strengths in the IV therapy market to drive future growth [24][26]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Company Overview - ICU Medical is a global MedTech company focused on IV therapy and critical care products, with sales in approximately 80 countries[6] - The company's diluted equity value is $3.82 billion, with a net debt of $1.02 billion (approximately 2.6x leverage) and an enterprise value of $4.84 billion[8] - The company's revenue is divided into three segments: Consumables (~$1.1B), Systems (~$680M), and Vital Care (~$300M)[7] - Geographically, 64% of sales are in the US & Canada, with the remaining in other regions[8] - Single-use disposables and software account for 87% of revenue, while hardware accounts for 13%[8] Growth Strategy - The company aims to deliver mid-single-digit growth across its core business[20] - The company is focused on expanding gross margins, with an opportunity for +200bps expansion remaining[37] - The company is developing a new IV therapy platform for launch in 2026, featuring a shared cloud-based enterprise software[24, 25] Innovation and Product Portfolio - The company has a complete IV therapy portfolio across the entire care continuum[15] - The company is focused on innovation in IV consumables to address clinical priorities such as patient and clinician safety and clinical efficiency[33] - The company is creating clinical value with IV consumables innovation, addressing impactful clinical priorities[33]

Group 1 - ICU Medical, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026, with their presentation scheduled for January 14, 2026, at 1:30 p.m. PT [1] - The presentation will be available via a live webcast on the company's website, with a replay option also provided [2] - ICU Medical is recognized as a global leader in infusion systems and critical care products, focusing on quality, innovation, and value for clinical customers [3]

Core Viewpoint - ICU Medical is nearing the end of a challenging integration and remediation process, which has been costly for the company [1] Group 1 - The company was previously rated a "Hold" due to the ongoing integration efforts [1]

Core Viewpoint - ICU Medical is nearing the end of a challenging integration and remediation process, which has been costly for the company [1] Group 1 - The company was previously rated a "Hold" due to the ongoing integration efforts [1]

ICU Medical FY Conference Summary Company Overview - **Company**: ICU Medical (NasdaqGS:ICUI) - **Industry**: Medical Technology Key Points Market Environment - The U.S. market for surgeries and hospital admissions appears healthy, with volumes increasing but not at a substantial rate year over year [6][8] - No significant decrease in hospital census; flu season is starting later than usual, but this does not heavily impact business [8][12] Capital Spending - Less than 10% of ICU Medical's $2 billion revenue comes from capital sales, primarily infusion pumps [12] - Capital purchases are necessary for modern devices, and U.S. customers are allocating capital as needed [12] Consumables Business Growth - The consumables segment has shown strong growth, compounding at 5-6% annually for over five years, driven by strong volumes and market share gains due to industry events like IV fluid shortages [14][15] - ICU Medical retains business gained from IV Solutions shortages, with limited competition in the market [15] Infusion Pumps - The infusion pump market is experiencing increased activity due to regulatory challenges faced by competitors, leading to more requests for proposals (RFPs) [21][22] - ICU Medical has a 20% share of the U.S. LVP (Large Volume Pump) install base, with opportunities for market share gains and technology refreshes expected to begin in late 2026 [32][34] Software and Technology Integration - ICU Medical is focusing on integrating its devices with a single software solution (LifeShield), enhancing ease of use and operational efficiency for hospitals [45][56] - The company believes that the new software will have long-term P&L implications by justifying higher pricing for software services [53][56] Financial Outlook - ICU Medical has seen gross margins improve from a low of 35% to around 41%, with a target of reaching 45% in the future [72][75] - The company is managing tariff impacts, with a current burden of $25 million, and is exploring operational adjustments to mitigate costs [70][72] Regulatory and Compliance - ICU Medical is in regular dialogue with the FDA regarding warning letters and product approvals, with most remediation work completed [81][83] - The company anticipates that the lifting of warning letters will be contingent on the approval of new products [81] Cash Management and Future Strategy - ICU Medical is focused on deleveraging to a target of two times debt, after which it may consider stock buybacks or other capital allocation strategies [84][96] - The company emphasizes the importance of innovation and product development in both pumps and consumables to drive future growth [88][90] Conclusion - ICU Medical is positioned in a healthy market environment with strong growth in consumables and opportunities in infusion pumps. The integration of software solutions and a focus on improving margins are key strategies moving forward. The company is also managing regulatory challenges and planning for future capital allocation once debt levels are optimized.